Marilyn Huckans1,2,3,4, Stephen Boyd5, Grant Moncrief1,2,6,7, Nathan Hantke1,2,8, Bethany Winters1,3,4, Kate Shirley1, Emily Sano1, Holly McCready1,3,4,9, Laura Dennis1,3,4,9, Milky Kohno1,4,9, William Hoffman1,2,3,4,9, Jennifer M Loftis1,3,4. 1. Research & Development Service, Veterans Affairs Portland Health Care System, Portland, OR, USA. 2. Mental Health and Clinical Neurosciences Division, Veterans Affairs Portland Health Care System, Portland, Or, USA. 3. Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA. 4. Methamphetamine Research Center, Oregon Health & Science University, Portland, Or, USA. 5. Department of Anesthesia and Perioperative Medicine, Oregon Health & Science University, Portland, Or, USA. 6. Pacific University, School of Graduate Psychology, Hillsboro, OR, USA. 7. Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 8. Department of Neurology, Oregon Health & Science University, Portland, OR, USA. 9. Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Or, USA.
Abstract
OBJECTIVE: To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs). METHOD: MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB). RESULTS: The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index. CONCLUSIONS: Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.
OBJECTIVE: To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs). METHOD: MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB). RESULTS: The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index. CONCLUSIONS: Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.
Entities:
Keywords:
Cognition; addiction; dependence; neuropsychological; stimulant; substance use disorder
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: John R Harsh; Roza Hayduk; Russell Rosenberg; Keith A Wesnes; James K Walsh; Sanjay Arora; Gwendolyn E Niebler; Thomas Roth Journal: Curr Med Res Opin Date: 2006-04 Impact factor: 2.580
Authors: William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell Journal: Psychopharmacology (Berl) Date: 2006-08-17 Impact factor: 4.530
Authors: Jennifer E Iudicello; Steven P Woods; Ofilio Vigil; J Cobb Scott; Mariana Cherner; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: J Clin Exp Neuropsychol Date: 2010-03-02 Impact factor: 2.475
Authors: Isabelle Boileau; Pablo Rusjan; Sylvain Houle; Diana Wilkins; Junchao Tong; Peter Selby; Mark Guttman; Jean A Saint-Cyr; Alan A Wilson; Stephen J Kish Journal: J Neurosci Date: 2008-09-24 Impact factor: 6.167
Authors: William F Hoffman; Daniel L Schwartz; Marilyn S Huckans; Bentson H McFarland; Gal Meiri; Alexander A Stevens; Suzanne H Mitchell Journal: Psychopharmacology (Berl) Date: 2008-08-07 Impact factor: 4.530